28 Apr 2020 - BrainChip Holdings (ASX:BRN BrainChip Holdings (ASX:BRN) CEO Lou DiNardo talks about its Akida integrated circuit, its advantages in event-based convolutional (e-conv) networks, applications and its move to wafer production and first engineering samples by Q3 2020.
27 Apr 2020 - Aus Tin Mining (ASX:ANW) CEO, Peter Williams talks farm-in agreement for exploration licences prospective for copper and gold in the Lachlan Fold Belt and proposal to divest its Granville Tin Mine.
27 Apr 2020 - Kazia Therapeutics (ASX:KZA) CEO & MD, Dr. James Garner talks about its Phase II interim results for its glioblastoma drug candidate paxasilib, its pivotal GBM AGILE Phase II clinical study to commence 2H20 and value drivers as the company moves toward registration.
24 Apr 2020 - Telix Pharmaceuticals (ASX:TLX), Chief Business Officer, David Cade talks about its prostate cancer imaging product, diagnostic and therapeutic products, partners and key priorities for 2020.
21 Apr 2020 - Cashwerkz (ASX:CWZ) newly appointed CEO, Jon Lechte talks about what attracted him to the role, and plans to drive growth for cash and fixed income products in a more uncertain economic environment.
15 Apr 2020 - MLC Senior Economist Bob Cunneen discusses the ongoing impact of the coronavirus on markets including central bank and government measures.
06 Apr 2020 - Cyclopharm (ASX:CYC) CEO & Managing Director, James McBrayer talks about its new drug application with the US FDA for Technegas and applications beyond pulmonary embolism in chronic chronic obstructive pulmonary ( COPD ) and asthma.
26 Mar 2020 - Lithium Consolidated Mineral Exploration Limited (ASX:LI3) Managing Director Andrew Haythorpe provides an update on the company's new WA projects prospective for gold, nickel and base metals, board changes and plans to improve the company’s prospects.
31 Mar 2020 - BluGlass Limited (ASX:BLG) Managing Director and CEO,Giles Bourne, talks about the company's 1:1 non-renounceable rights issue, the need to fund its technology through to commercialisation, independent validation of its RPCVD technology and its response to COVID-19.
31 Mar 2020 - Cynata Therapeutics Limited (ASX:CYP) Managing Director, Dr Ross MacDonald, talks 1H20 results, upcoming Phase 2 clinical trials, licensing and strategy to build the company's Cymerus cell therapy platform.
